CoChat

5-HT3 Receptor Antagonism: A Potential Therapeutic Approach for the Treatment of Depression and other Disorders

Open access

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.

Abstract

Background: Depression or Major depressive disorder (MDD) is a prolonged condition of sadness. MDD is the most common mental disorder that affects more than 264 million people worldwide. According to the monoamine hypothesis, serotonin (5-hydroxy tryptamine, 5-HT), dopamine (DA) and norepinephrine (NE) are the major neurotransmitters (NTs) involved in depression. Methods: The methodology adopted for writing this review article is essentially based on the secondary literature search through a systematic literature review. This review mainly focussed on the role of 5-HT 3 receptor antagonists (5-HT 3 RA) in depression and comorbid disorders like anxiety. Results: Out of three major NTs mentioned above, serotonin has a predominant role in the pathophysiology of depression. The serotonin type-3 receptors (5-HT 3 R) are well renowned to be expressed in the central nervous system (CNS) in regions which have significance in the vomiting reflex, perception of pain, the reward system, cognition, depression and anxiety control. 5-HT 3 R are the receptors of serotonergic family that belong to ligand-gated ion channel. 5-HT 3 RA inhibit the binding of serotonin to postsynaptic 5-HT 3 R and increases its availability to other receptors like 5- HT 1A, 1B and 1D as well as 5-HT 2 receptors and produces anti-depressant-like effect. 5-HT 3 RA also have an important role in mood and stress disorders. Some of the studies have shown the effectiveness of these agents in stress disorder. Conclusion: The present article focussed on the role of 5-HT 3 R and their antagonists in the treatment of depression and anxiety. Further studies are warranted to prove their efficacy with respect to other standard anti-depressants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x18666201015155816

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) Causes of depression. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (1) Causes of depression. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central
Fig. (2) Structure of the 5-HT3 receptor. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (2) Structure of the 5-HT3 receptor. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central
Fig. (3) Chemical structures of serotonin and competitive 5-HT3 receptor antagonists.
Fig. (3) Chemical structures of serotonin and competitive 5-HT3 receptor antagonists.CC BY-NC · PubMed Central
Fig. (4) Basic pharmacophore of 5-HT3 receptor antagonists.
Fig. (4) Basic pharmacophore of 5-HT3 receptor antagonists.CC BY-NC · PubMed Central
Fig. (5A) Chemical structures of non-competitive antagonists.
Fig. (5A) Chemical structures of non-competitive antagonists.CC BY-NC · PubMed Central
Fig. (5B) Chemical structures of non-competitive antagonists.
Fig. (5B) Chemical structures of non-competitive antagonists.CC BY-NC · PubMed Central
Fig. (6) Involvement of 5-HT3 receptor antagonists in various disorders.
Fig. (6) Involvement of 5-HT3 receptor antagonists in various disorders.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Research works printed but not linked: 2

  1. [2]Center for substance abuse treatment. Managing depressive symptoms in substance abuse clients during early recovery. 2008 https://www.ncbi.nlm.nih.gov/books/NBK64063/ 22514854
  2. [102]Preston G.C. 5-HT3 Antagonists and dosorders of cognition. Racagni, G.; Brunello, N.; Langer, S.Z.; editors. Recent Advances in the treatment of neurodegenerative diorders and cognitive dysfunction International Academy of Biomedical Drug Research Karger, Basel, Switzerland. 1994 7 89 93

Cited by

See all 131

Metadata

Authors
Bhatt, S., Devadoss, T., Manjula, S. N., & Rajangam, J.
Affiliations
  • Amity University Madhya Pradesh (IN)
  • Department of Pharmaceutical Chemistry, K. V. S. R. Siddhartha College of Pharmaceutical Sciences, Siddhartha Nagar, Vijayawada, Andhra Pradesh-520010,India
  • JSS Academy of Higher Education and Research (IN)
  • Department of Pharmacology, Sree Vidyanikethan College of Pharmacy – Tirupati-517 501, Andhra Pradesh,India
Corresponding author
Bhatt, Shvetank
Venue
Current Neuropharmacology
Published
2021-09
Volume
19
Issue
9
Pages
1545-1559
ISSN
1570-159X (ISSN-L)
OpenAlex
W3093393128
Cited by
119
References
120
Citations by year
2026: 36 · 2025: 27 · 2024: 30 · 2023: 18 · 2022: 7 · 2021: 1
FWCI
3.90
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
5-HT3 receptor antagonists, depression, major depressive disorder, anxiety, serotonin, monoamine hypothesis, ligand-gated ion channels, antidepressant efficacy, stress disorders, comorbidities
MeSH terms
Anxiety Disorders, Depression, Major Depressive Disorder, Depressive Disorder, Major, Humans, Serotonin, Receptors, Serotonin, 5-HT3, Serotonin 5-HT3 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-HT3 Receptor Antagonism: A Potential Therapeutic Approach for the Treatment of Depression and other Disorders. https://app.cochat.ai/papers/10.2174/1570159x18666201015155816
The paper
Bhatt, S., Devadoss, T., Manjula, S. N., & Rajangam, J. (2021). 5-HT3 Receptor Antagonism: A Potential Therapeutic Approach for the Treatment of Depression and other Disorders. Current Neuropharmacology. https://doi.org/10.2174/1570159x18666201015155816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.